Get started
Author

Lutz Uharek

Observed names: LUTZ UHAREK, Uharek Lutz, Uharek, Lutz
Observed institutions: Academia Nacional de Medicina, German Cancer Research Center, University of Hull, Justus-Liebig-Universität Gießen, Heidelberg University, Universidad de Buenos Aires, Universitätsmedizin Greifswald, University Medical Center Freiburg, Christian-Albrechts-Universität zu Kiel, Universität Greifswald, Humboldt-Universität zu Berlin, Munich Leukemia Laboratory (Germany), University Medical Center Hamburg-Eppendorf, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Deutsches Konsortium für Translationale Krebsforschung, Stiftung Charité, Hull York Medical School, Freie Universität Berlin, Charité – Universitätsmedizin Berlin, Ludwig-Maximilians-Universität München, Leipzig University, Otto-von-Guericke-Universität Magdeburg
OpenAlex ID: A5110458317
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
2009 · Nicolaus Kröger, Ernst Holler, et al. · Blood · 393
PDF
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
2010 · Peter Dreger, Hartmut Döhner, et al. · Blood · 305
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
2009 · Ulrich Keilholz, Anne Letsch, et al. · Blood · 300
Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions—A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
2014 · Thomas Schroeder, Elena Rachlis, et al. · Transplantation and Cellular Therapy · 192
PDF
Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change
2013 · Maximilian Christopeit, Oliver Kuss, et al. · Journal of Clinical Oncology · 175
PDF
Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells
2000 · Christof Lehmann, Matthias Zeis, et al. · Blood · 109
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
2013 · Peter Dreger, Andrea Schnaiter, et al. · Blood · 106
Activation of natural killer cells with interleukin 2 (IL‐2) and IL‐12 increases perforin binding and subsequent lysis of tumour cells
2001 · Christof Lehmann, Matthias Zeis, et al. · British Journal of Haematology · 99
Efficacy of the interleukin‐2 receptor antagonist basiliximab in steroid‐refractory acute graft‐versus‐host disease
2005 · Martin Schmidt‐Hieber, Thomas Fietz, et al. · British Journal of Haematology · 94
PDF
Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell–depleted reduced-intensity transplantation
2006 · Ralf G. Meyer, Cedrik M. Britten, et al. · Blood · 90
PDF
The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells
2006 · Lars Fischer, Olaf Penack, et al. · Experimental Hematology · 81
PDF
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial
2017 · Isabelle Krämer, Stephan Stilgenbauer, et al. · Blood · 79
PDF
Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study
2010 · Wolfgang A. Bethge, Thoralf Lange, et al. · Blood · 76
Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation
2006 · Jakob R. Passweg, Ulrike Koehl, et al. · Best Practice & Research Clinical Haematology · 67
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
2011 · Clemens-Martin Wendtner, Peter Hillmen, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 60
Allogeneic Peripheral Blood Progenitor Cell Transplantation in a Murine Model: Evidence for an Improved Graft-Versus-Leukemia Effect
1997 · Bertram Glass, Lutz Uharek, et al. · Blood · 58
PDF
Utilization of TREC and KREC quantification for the monitoring of early T- and B-cell neogenesis in adult patients after allogeneic hematopoietic stem cell transplantation
2013 · Angela Mensen, Christoph Ochs, et al. · Journal of Translational Medicine · 56
PDF
Graft‐versus‐leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells
1996 · Bertram Glass, Lutz Uharek, et al. · British Journal of Haematology · 56
Central nervous system infections in immunocompromised patients – update on diagnostics and therapy
2008 · Martin Schmidt-Hieber, Janine Zweigner, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 53
Allogeneic Nk Cells as Potent Antileukemic Effector Cells After Allogeneic Bone Marrow Transplantation in Mice
1995 · Matthias Zeis, Lutz Uharek, et al. · Transplantation · 48
Single-Nucleotide Polymorphisms Within the Thrombomodulin Gene (THBD) Predict Mortality in Patients With Graft-Versus-Host Disease
2014 · Sivaramakrishna P. Rachakonda, Olaf Penack, et al. · Journal of Clinical Oncology · 46
Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2
2005 · Robert Godal, Ulrich Keilholz, et al. · Blood · 39
The type of ATG matters — Natural killer cells are influenced differentially by Thymoglobulin, Lymphoglobulin and ATG-Fresenius
2007 · Olaf Penack, Lars Fischer, et al. · Transplant Immunology · 38
Tracking in vivo dynamics of NK cells transferred in patients undergoing stem cell transplantation
2014 · Monica Killig, Birte Friedrichs, et al. · European Journal of Immunology · 27
PDF
Impaired Function of Dendritic Cells Deficient in Angiotensin II Type 1 Receptors
2010 · Karen Nahmod, Ciara Gentilini, et al. · Journal of Pharmacology and Experimental Therapeutics · 26
PDF
Works count: 136
Citation count: 3,110
H-index: 25
I10-index: 44
Year
Topic
Type